KR20130074825A - Antimicrobial composition comprising bifidobaterium having antibacterial activity against propionibacterium acnes, and extract of germinated soybean - Google Patents

Antimicrobial composition comprising bifidobaterium having antibacterial activity against propionibacterium acnes, and extract of germinated soybean Download PDF

Info

Publication number
KR20130074825A
KR20130074825A KR1020110141285A KR20110141285A KR20130074825A KR 20130074825 A KR20130074825 A KR 20130074825A KR 1020110141285 A KR1020110141285 A KR 1020110141285A KR 20110141285 A KR20110141285 A KR 20110141285A KR 20130074825 A KR20130074825 A KR 20130074825A
Authority
KR
South Korea
Prior art keywords
acne
composition
lactic acid
extract
acnes
Prior art date
Application number
KR1020110141285A
Other languages
Korean (ko)
Inventor
하남주
이강오
Original Assignee
삼육대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 삼육대학교산학협력단 filed Critical 삼육대학교산학협력단
Priority to KR1020110141285A priority Critical patent/KR20130074825A/en
Publication of KR20130074825A publication Critical patent/KR20130074825A/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/10—Preparation or pretreatment of starting material
    • A61K2236/19—Preparation or pretreatment of starting material involving fermentation using yeast, bacteria or both; enzymatic treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cosmetics (AREA)

Abstract

PURPOSE: An anti-acne composition containing a germinated soybean extract and lactic acid bacteria which suppresses Propionibacterium acnes is provided to specifically suppress P. acnes which cause acne, to ensure antibacterial action against P. acne and harmful bacteria, and to prevent and treat acne diseases. CONSTITUTION: An anti-acne composition contains a germinated soybean extract and lactic acid bacteria which suppress Propionibacterium acnes. The extract is prepared using water, C1-C5 alcohols, propylene glycol, 1,3-butylene glycol, or a mixture thereof. The antibacterial composition has an antibacterial activity against one or more selected from the group consisting of E.coli, Salmonella typhimurium, Staphyllococcus aureus, Candida albican, Aspergillus niger, and Propionibacterium acnes. The lactic acid bacteria are Bipidobacterium lactobacillus SPM0308 (KCTC 11669BP). A drug, a health functional food, or a cosmetic composition contains the composition.

Description

발아콩 추출물 및 항여드름균 활성을 나타내는 유산균을 포함하는 항여드름 조성물{ANTIMICROBIAL COMPOSITION COMPRISING BIFIDOBATERIUM HAVING ANTIBACTERIAL ACTIVITY AGAINST PROPIONIBACTERIUM ACNES, AND EXTRACT OF GERMINATED SOYBEAN}ANTIMICROBIAL COMPOSITION COMPRISING BIFIDOBATERIUM HAVING ANTIBACTERIAL ACTIVITY AGAINST PROPIONIBACTERIUM ACNES, AND EXTRACT OF GERMINATED SOYBEAN}

본 발명은 발아콩 추출물 및 항여드름균 활성을 나타내는 유산균을 포함하는 항여드름 조성물에 관한 것으로서, 더욱 상세하게는 항염증 활성을 갖는 발아콩 추출물과, 프로피오니박테리움 아크네스(propionibacterium acnes)에 대한 항균 활성을 가지는 신규한 비피도박테리움 유산균 SPM0308, 또는 이의 배양물을 유효 성분으로 함유하는 항여드름균 조성물에 대한 것이다.
The present invention relates to an anti-acne composition comprising a germinated soybean extract and lactic acid bacteria exhibiting anti-acne bacterium activity, and more specifically, to a germinated soybean extract having anti-inflammatory activity and propionibacterium acnes. A novel Bifidobacterium lactic acid bacterium SPM0308 having an antimicrobial activity, or a culture thereof, as an active ingredient, comprising an anti acne bacterium composition.

프로피오니박테리움 아크네스(P. acnes: 아크네스 바실러스)는 혐기성 그램 양성 무포자 바실러스이고, 피부 및 장관에 존재하고 있다. 본래 사람에 대해서는 병원성이 낮은 것으로 생각되어 왔지만, 최근의 연구로부터 일부 만성 질병의 발병, 진행에 중요한 역할을 하고 있다는 것이 밝혀졌다. P. acnes는 1) 보체를 활성화하고, 2)호중구의 주화성 인자를 생산하며, 3) 호중구에 의한 효소 방출을 유발하는 등, 면역계를 강하게 활성화한다.Propionibacterium Acnes (Acnes Bacillus) is an anaerobic Gram-positive sporeless Bacillus and is present in the skin and intestines. Although pathogenicity was originally thought to be low in humans, recent studies have shown that it plays an important role in the development and progression of some chronic diseases. P. acnes strongly activates the immune system, including 1) activating complement, 2) producing chemotactic factors of neutrophils, and 3) causing enzyme release by neutrophils.

P. acnes가 발병, 진행에 관여하는 질병으로는 예를 들어 여드름, 사코이드증, 포도막염, 결막염, 각막염, 각막플릭텐, 심내막염, 척추관절염 등이 포함된다. 이런 이유로, P. acnes에 대해 우수한 항균작용을 가지는 약제의 개발이 요구되고 있다. 특히, 여드름은 지선성 모낭에 영향을 주는 만성 염증성 질병이고, 피부발진과 함께 안면, 경부, 가슴등에 호발한다. 면포, 붉은 구진, 농포, 경결, 소결절, 낭종 및 흉터 등과 같은 다양한 피부발진이 혼재하여 나타난다. 여드름은 통상 미소면포로부터 폐쇄면포가 형성되고, 그것이 개방면포 또는 염증성 면포인 붉은 구진, 농포로 이행되며, 중요한 경우는 여드름 흉터 등의 후유증이 남는다. 또한, 여드름은 청년 등에 있어서는 정신적 고뇌의 원인도 되기 때문에, 적절한 치료가 요구된다. 여드름은 모포중에 존재하는 P. acnes가 리파아제를 생산하고, 피지성분 중의 트리글리세리드를 유리지방산으로 분해한다. 유리지방산은 모루두 상피를 자극해서 과각화를 일으키고, 면포형성을 유도한다. 게다가, P. acnes는 호중구 주화성 인자, 보체 활성화 인자, 프로테아제, 히알루노니다제 등을 생산하고, 병환부에 호중구가 유도되며, 모포상피를 파괴한다. 결과로서, 병환부에 고름집이 생성된다 (Shigeo Ikeda, eds., "Hyojun Hifukagaku (6th edition)" pages 270 ~ 272, Igaku-Shoin 발행, 2001를 참조). 따라서, 여드름 치료제로서는 P. acnes에 대한 항균작용이 증가되고, 과각화 억제작용, 호중구 유도에 의한 염증의 억제작용을 함께 가지는 약제가 요망된다.
Diseases involved in the development and progression of P. acnes include, for example, acne, sarcoidosis, uveitis, conjunctivitis, keratitis, corneal folliten, endocarditis and spondyloarthritis. For this reason, there is a need for the development of a drug having excellent antimicrobial activity against P. acnes. Acne, in particular, is a chronic inflammatory disease that affects chiropractic hair follicles and causes skin rashes on the face, neck and chest. Various skin rashes such as cotton vesicles, red papules, pustules, indurations, sintered sections, cysts and scars appear in a mixture. Pimples usually form closed vesicles from microvesicles, which migrate to open papules or inflammatory papules, red papules, pustules, and in important cases, sequelae such as acne scars remain. In addition, acne is a cause of mental anguish in young people and the like, so proper treatment is required. In acne, P. acnes, which is present in the hair follicles, produces lipases and breaks down triglycerides in sebum. Free fatty acid stimulates anvil epithelium, causing hyperkeratosis, and induces scleroderma. In addition, P. acnes produces neutrophil chemotactic factors, complement activating factors, proteases, hyaluronidase, and the like, induces neutrophils in the affected area and destroys the blast epithelium. As a result, pus is produced in the diseased area (see Shigeo Ikeda, eds., "Hyojun Hifukagaku (6th edition)" pages 270-272, published by Igaku-Shoin, 2001). Therefore, as an acne treatment agent, an antimicrobial action against P. acnes is increased, and a drug having both an anti-keratogenic action and an inhibitory effect of neutrophil induction is desired.

이러한 염증성 여드름 질환에 관련된 임상적 치료요법에 있어서는, 주로 테트라사이클린(tetracycline), 신다마이신(cindamycine), 에리스로마이신 (erythromycin) 등의 항생제가 주로 이용되어 왔으나, 이러한 항생제를 장기간 투여할 경우, 여드름의 원인균이 내성을 가지게 됨으로써, 치료효과가 떨어지는 문제점이 있었으며, 여드름 유발균인 P. acnes는 그 인위적 배양이 어려워서, 이들 약제에 대한 감수성 실험이 미약할 수 밖에 없으므로, 적절한 약제선정에 어려움이 따랐다.
In clinical therapies related to inflammatory acne diseases, antibiotics such as tetracycline, cindamycin, and erythromycin have been mainly used. However, when such antibiotics are administered for a long time, As the causative bacteria became resistant, there was a problem that the treatment effect was inferior, and P. acnes, which is an acne-causing bacterium, was difficult to artificially cultivate, and thus the sensitivity test for these drugs was inevitably difficult.

본 발명은 상기와 같은 종래 기술의 문제점을 해결하기 위하여 천연 추출물 및 유산균을 포함하는 새로운 항여드름 조성물을 제공하는 것을 목적으로 한다.
The present invention aims to provide a new anti-acne composition comprising a natural extract and lactic acid bacteria in order to solve the problems of the prior art as described above.

본 발명은 상기와 같은 과제를 해결하기 위하여 발아콩 추출물 및 항여드름균 활성을 나타내는 유산균을 포함하는 항여드름 조성물을 제공한다.
The present invention provides an anti-acne composition comprising a lactic acid bacterium showing germinated bean extract and anti-acne bacterium activity in order to solve the above problems.

본 발명에 있어서, 상기 추출물은 물, 탄소수 1 내지 5의 알코올, 프로필렌글리콜, 1,3-부틸렌글리콜 또는 이들의 혼합용매를 추출용매로 사용하여 제조한 것을 특징으로 한다. In the present invention, the extract is characterized in that it is prepared using water, alcohol having 1 to 5 carbon atoms, propylene glycol, 1,3-butylene glycol or a mixed solvent thereof as an extraction solvent.

본 발명에서 발아콩이란 콩과에 속하는 일년생 초본인 콩을 발아시킨 것이다. 상기 콩은 일반적으로 알려진 모든 종류를 포함하여 특별히 제한되지 않는다. 구체적으로, 상기 콩은 서리태, 완두콩, 풋콩, 흰 강낭콩, 빨간 강남콩, 검정콩, 서목태, 발콩, 청태 등일 수 있으며, 바람직하게는 메주콩 또는 검정콩일 수 있고, 더욱 바람직하게는 검정콩일 수 있다.Germinated beans in the present invention is a germination of a year-old herb beans belonging to the legumes. The beans are not particularly limited, including all commonly known varieties. Specifically, the soybean may be frosted, peas, green beans, white kidney beans, red kidney beans, black beans, Seomoktae, bal beans, cheongtae, etc., preferably may be meju beans or black beans, more preferably black beans.

상기 발아콩은 상기 콩을 발아시켜 콩의 싹이 0.5 cm 내지 1 cm 정도 자란 것일 수 있으나, 본 발명이 콩의 싹의 길이에 제한되는 것은 아니다. 구체적으로, 세척한 콩을 발아시킨 것으로서, 상기 발아콩 또는 발아콩의 추출물은 각종 아미노산, 미네랄, 효소, 비타민, 이소플라본을 함유하고 있다. 또한, 상기 발아콩의 제조방법 및 식품에의 이용은 주로 알려져 있다.The germinated soybean germination of the soybean sprout may be grown to about 0.5 cm to 1 cm, but the present invention is not limited to the length of the shoot of the bean. Specifically, as the germinated washed beans, the germinated beans or extracts of germinated beans contain various amino acids, minerals, enzymes, vitamins, isoflavones. In addition, the production method of the germinated bean and its use in food are mainly known.

상기 발아콩은 상기 콩에 대해 수침 단계 및 발아 단계를 수행하여 제조할 수 있으나, 상기 발아콩의 제조방법은 특별히 제한되는 것은 아니다. 또한, 상기 발아콩은 수침 단계 및 발아 단계를 수행한 후에 추가로 건조 단계를 수행할 수 있다.The germinated bean may be prepared by performing a immersion step and a germination step for the soybeans, but the method for producing the germinated soybeans is not particularly limited. In addition, the germinated soybeans may further perform a drying step after performing the immersion step and the germination step.

상기 수침 단계는 정제수를 이용하여10 ℃ 내지 35 ℃, 바람직하게는 15 ℃ 내지 30 ℃, 더욱 바람직하게는 20 ℃ 내지 30 ℃에서 12 시간 내지 72 시간, 바람직하게는 16 시간 내지 60 시간, 더욱 바람직하게는 24 시간 내지 48 시간 동안 수침시켜 수행할 수 있다. 상기 정제수는 발아콩의 질량을 기준으로 5 배 내지 20 배, 바람직하게는 10 배 내지 15배의 물을 이용할 수 있다.The immersion step is 12 to 72 hours, preferably 16 to 60 hours, more preferably at 10 ℃ to 35 ℃, preferably 15 ℃ to 30 ℃, more preferably 20 ℃ to 30 ℃ using purified water. Preferably soaked for 24 to 48 hours. The purified water may be used 5 times to 20 times, preferably 10 times to 15 times water based on the mass of the germinated beans.

또한, 상기 발아 단계는 10 ℃ 내지 35 ℃, 바람직하게는 15 ℃ 내지 30 ℃, 더욱 바람직하게는 20 ℃ 내지 30 ℃에서 24 시간 내지 144 시간, 바람직하게는 48 시간 내지 120 시간, 더욱 바람직하게는 72 시간 내지 96 시간 수행할 수 있다.In addition, the germination step is 24 to 144 hours, preferably 48 to 120 hours, more preferably at 10 ℃ to 35 ℃, preferably 15 ℃ to 30 ℃, more preferably 20 ℃ to 30 ℃ 72 hours to 96 hours.

보다 구체적으로는, 상기 발아콩은 세척한 메주콩 또는 검정콩에 10배수의 정제수를 넣고 20 ℃ 내지 30 ℃에서 수침 24 시간 내지 48시간 수침시킨 후에, 상기 수침된 콩을 건져내어 20 ℃ 내지 30 ℃에서 72 시간 내지 96 시간 동안 발아시키는 단계를 거쳐 제조할 수 있다.More specifically, the germinated soybeans are put into 10 times the purified water in the washed soybean or black soybeans soaked at 20 ℃ to 30 ℃ for 24 hours to 48 hours, then the soaked beans are picked up at 20 ℃ to 30 ℃ It can be prepared through the step of germination for 72 to 96 hours.

본 발명의 발아콩 추출물은 통상의 식물 추출물의 제조방법에 따라 제조된 것일 수 있다.
Germinated bean extract of the present invention may be prepared according to a conventional method for producing a plant extract.

본 발명에 있어서, 항균 조성물이란 항미생물제를 총칭하는 의미인 항생제와 같은 의미일 수 있고, 항균제, 살균제, 방부제, 보존제 또는 제균제와 같은 의미일 수 있으며, 바람직하게는 그람 양성균 및 그람 음성균의 발육 과 생활 기능을 저지 또는 억제할 수 있는 물질을 의미한다. 본 발명에 있어서, 상기 항균 조성물은 대장균(E.coli), 살모넬라 티피뮤리움(Salmonella typhimurium), 스타필로 코커스 아우레우스(Staphyllococcus aureus), 칸디다 균(Candida albican), 흙곰팡이(Aspergillus niger) 또는 여드름균(Propionibacterium acnes)으로 이루어진 군에서 선택된 1종 이상에 대해 항균활성을 갖는 것을 특징으로 한다. In the present invention, the antimicrobial composition may have the same meaning as an antibiotic which is a generic term for an antimicrobial agent, and may have the same meaning as an antimicrobial agent, a fungicide, a preservative, a preservative or an antimicrobial agent, and preferably the development of Gram-positive bacteria and Gram-negative bacteria. Means a substance that can inhibit or inhibit life and life functions. In the present invention, the antimicrobial composition is E. coli, Salmonella typhimurium, Staphyllococcus aureus, Candida albican, Mold fungus (Aspergillus niger) or It is characterized by having antimicrobial activity against at least one selected from the group consisting of acne bacteria (Propionibacterium acnes).

상기 프로피오니박테리움 아크네스(P. acnes: 아크네스 바실러스)는 혐기성 그램 양성 무포자 바실러스이고, 피부 및 장관에 존재하고 있다. 본래 사람에 대해서는 병원성이 낮은 것으로 생각되어 왔지만, 최근의 연구로부터 일부 만성 질병의 발병, 진행에 중요한 역할을 하고 있다는 것이 밝혀졌다. P. acnes는 1) 보체를 활성화하고, 2)호중구의 주화성 인자를 생산하며, 3) 호중구에 의한 효소 방출을 유발하는 등, 면역계를 강하게 활성화한다.
P. acnes (Acnes Bacillus) is an anaerobic Gram-positive sporeless Bacillus and is present in the skin and intestinal tract. Although pathogenicity was originally thought to be low in humans, recent studies have shown that it plays an important role in the development and progression of some chronic diseases. P. acnes strongly activates the immune system, including 1) activating complement, 2) producing chemotactic factors of neutrophils, and 3) causing enzyme release by neutrophils.

본 발명에 있어서, 상기 항여드름균 활성을 나타내는 유산균은 비피도박테리움 유산균 SPM0308 (KCTC 11669BP) 인 것을 특징으로 한다. In the present invention, the lactic acid bacteria exhibiting anti-acne bacteria activity is characterized in that the Bifidobacterium lactic acid bacteria SPM0308 (KCTC 11669BP).

본 발명은 항균 활성을 갖는 신규 유산균인 비피도박테리움 유산균 SPM0308의 분리 및 동정, 나아가 본 발명에 따른 신규 유산균의 여드름 원인균에 대한 항균 활성 테스트로 구성된다.
The present invention consists of isolation and identification of a novel lactic acid bacterium Bifidobacterium lactic acid bacteria SPM0308 having antibacterial activity, and furthermore, an antibacterial activity test against acne causing bacteria of the novel lactic acid bacteria according to the present invention.

본 발명에서 사용된 비피도박테리움 유산균 SPM0308 균주는 2010년 4월 7일자로 대한민국 특허균주 기탁기관인 한국과학기술연구소 생명공학연구소 내 유전자원센타에 기탁하여 기탁번호 KCTC 11669BP를 부여받은 바 있다.
The Bifidobacterium lactobacillus SPM0308 strain used in the present invention was deposited on April 7, 2010 at the Genetic Resources Center in the Korea Institute of Science and Technology Biotechnology Research Institute, which is a depository institution for Korean patent strains, and was given the accession number KCTC 11669BP.

본 발명은 또한, 본 발명에 의한 조성물을 포함하는 약제, 건강기능식품 또는 화장료조성물을 제공한다.
The present invention also provides a pharmaceutical, health functional food or cosmetic composition containing the composition according to the present invention.

본 발명에 따르는 비피도박테리움 유산균 SPM0308 균주 및 상기 비피도박테리움 유산균 SPM0308 또는 이의 배양물과 발아콩 추출물을 유효 성분으로 함유하는 항여드름균 조성물은 여드름 원인균인 P. acnes(프로피오니 박테리움 에크네스)에 대하여 특이적 저해 활성 기능을 가지고 있어 피부에 서식하는 여드름 원인균 및 유해 세균에 대하여 항균 작용을 발휘하여 여드름 질환을 치료하고 예방할 수 있다.
Bifidobacterium lactic acid bacteria SPM0308 strain according to the present invention and the anti-acne bacterium composition containing the Bifidobacterium lactic acid bacteria SPM0308 or its culture and germinated bean extract as an active ingredient is P. acnes (propioni bacterium Ac. Because it has a specific inhibitory activity against nes), it can exert antibacterial action against acne causing bacteria and harmful bacteria in the skin to treat and prevent acne disease.

도 1은 항균 활성을 나타내는 균주의 선발 결과를 나타낸다. Figure 1 shows the selection results of strains showing antimicrobial activity.

이하, 실시예에 따라서 본 발명을 보다 구체적으로 설명하지만, 본 발명이 이하의 실시예에 의해 한정되는 것은 아니다.
Hereinafter, although an Example demonstrates this invention more concretely, this invention is not limited by the following example.

<< 실시예Example 1>  1> 비피도박테리움Bifidobacterium 아돌레센티스Adolescentes SPMSPM 0308 분리 및 동정 0308 Isolation and Identification

<< 실시예Example 1-1> 인분으로부터 유산균의 분리 1-1> Isolation of Lactobacillus from Servings

정상적인 섭식 습관을 갖는 20-30세의 건강한 성인 15명으로부터 분변을 수집하였다. 이후, BBL의 혐기성 샘플 컬렉션 & 트랜스포트 시스템(BBL's anerobic sample collection & transport system)을 이용하여 편성 혐기성(obligate anaerobic) 유산균을 분리하였다.Fecals were collected from 15 healthy adults aged 20-30 with normal eating habits. Subsequently, obligate anaerobic lactic acid bacteria were isolated using BBL's anaerobic sample collection & transport system.

수집된 인분의 적당량을 생리식염수 100 ㎖에 현탁한 후, 적당량을 취하여 5% 양 혈청이 함유된 BL 아가 배지(Blood-Liver, Nissue)에 도말하였다. 박트론 혐기 챔버(Bactron Anaerobic chamber; Sheldon Manufacturing Inc.)를 이용하여 37?에서 48시간 동안 배양하였다. 생존한 균주 중에서 0.5-2.0 mm 의 적갈색 중심 부분을 갖는 밝은 갈색, 유백색 또는 황갈색 형태의 비피도박테리움 속 미생물을 선별하였다. 선별된 유산균은 총 3 종이며, 이들을 각각 SPM 0308, SPM1005, SPM1207로 명명하였다.
An appropriate amount of the collected phosphorus was suspended in 100 ml of physiological saline, and then an appropriate amount was taken and spread on BL agar medium (Blood-Liver, Nissue) containing 5% sheep serum. It was incubated for 48 hours at 37 ° using a Bactron Anaerobic chamber (Ssheldon Manufacturing Inc.). Among the surviving strains, Bifidobacterium spp. Microorganisms of light brown, milky white or tan color with a reddish brown central portion of 0.5-2.0 mm were selected. A total of three lactic acid bacteria were selected, and they were named SPM 0308, SPM1005, and SPM1207, respectively.

<< 실시예Example 1-2> 항균 활성을 나타내는 균주의 선발 1-2> Selection of strains showing antimicrobial activity

상기 실시예 1-1 에서 분리된 유산균들 중에서 여드름 원인균의 성장 저해 및 항균 활성을 가진 유산균을 선별하였다.
Among the lactic acid bacteria isolated in Example 1-1, lactic acid bacteria having growth inhibition and antibacterial activity of acne causing bacteria were selected.

여드름 원인균으로서 한국생명공학연구원의 유전자은행 (Korean Collection for Type Cultures, KCTC)으로부터 P. acnes KCTC 3320을 입수하였다. P. acnes KCTC 3320은 37?에서 48시간동안 Reinforced clostridial (RC) 배지 (Difco, USA)에서 무산소로 배양되었다(Bactron Anaerobic Chamber, Sheldon Manufacturing Inc., USA)
P. acnes KCTC 3320 was obtained from the Korean Collection for Type Cultures (KCTC) of the Korea Research Institute of Bioscience and Biotechnology. P. acnes KCTC 3320 was incubated anaerobicly in Reinforced clostridial (RC) medium (Difco, USA) for 48 hours at 37 ° C (Bactron Anaerobic Chamber, Sheldon Manufacturing Inc., USA)

배양된 P. acnes KCTC 3320을 서스펜션 형식으로 준비하고, 여기에 상기 분리된 유산균 SPM 0308, SPM1005, SPM1207을 1:1 비율로 혼합하고 8ml RC 배지에 첨가한 후 10초간 보텍스 믹스하였다. 그 후 무산소 환경(90% N2, 5% H2, 5% CO2) 하 120분간 37 ℃에서 배양시켰다. 대조군으로 P. acnes 서스펜션이 같은 양의 PBS와 혼합되었다. 배양 후, 각 서스펜션에 있는 P. acnes CFU가 평판계수법(plate count technique)으로 측정되었다. 그리고, P. acnes 생존률은 아래와 같은 식을 사용하여 측정하였다.
Cultured P. acnes KCTC 3320 was prepared in a suspension form, and the isolated lactic acid bacteria SPM 0308, SPM1005, and SPM1207 were mixed in a 1: 1 ratio and added to 8 ml RC medium, followed by vortex mixing for 10 seconds. Thereafter, the cells were incubated at 37 ° C. for 120 minutes in an anaerobic environment (90% N 2 , 5% H 2 , 5% CO 2 ). P. acnes as a control The same amount of suspension Mixed with PBS. After incubation, P. acnes CFU in each suspension was measured by the plate count technique. And P. acnes Survival was measured using the equation below.

P. acnes 생존률 = P. acnes Survival rate =

(CFU of P. acnes incubated with Bifidobacter)/CFU of P. acnes incubated with PBS) ×100
(CFU of P. acnes incubated with Bifidobacter) / CFU of P. acnes incubated with PBS) × 100

결과는 평균± 표준편차로 표현되었다. 자료의 통계적 평가를 위해, SPSS 15.0를 사용하여 one-way ANOVA가 적용되었다. 그 후 터키 검정법을 이용해 사후 검정 비교하였으며, 그 결과를 도 1에 나타내었다. 도 1에서 보는 바와 같이 SPM0308 에 의한 항균 효과와 대조군 및 다른 유산균 SPM1005, SPM1207 에 의한 항균 효과의 차이에 대한 통계처리 결과 p<0.05으로 SPM0308 에 의한 항균 효과와 대조군 및 다른 유산균에 의한 항균 효과의 차이가 매우 크다는 것을 알 수 있다.
Results are expressed as mean ± standard deviation. For statistical evaluation of the data, one-way ANOVA was applied using SPSS 15.0. Then, the post hoc test was compared using the Turkish test method. The results are shown in FIG. 1. As shown in FIG. 1, statistical results of the antimicrobial effect of SPM0308 and the antimicrobial effect of the control group and other lactic acid bacteria SPM1005 and SPM1207 were p <0.05. It can be seen that is very large.

본 발명에 따른 유산균주는 비피도박테리움 아돌레센티스 SPM0308 로 명명하고 2010년 4월 7일자로 대한민국 특허균주 기탁기관인 한국과학기술연구소 생명공학연구소 내 유전자원센타에 기탁하여 기탁번호 KCTC 11669BP를 부여받았다.
Lactobacillus according to the present invention was named Bifidobacterium adolescents SPM0308 and was deposited on April 7, 2010 in the Genetic Resources Center of the Korea Institute of Science and Technology, Korea Institute of Science and Technology, which was deposited with the Korean patent strain and received the accession number KCTC 11669BP. .

<실시예 2: 발아콩 추출물의 제조>Example 2: Preparation of Germinated Bean Extract

시중에서 구매한 검정콩의 질량을 기준으로 10배의 정제수를 넣고 25 ℃에서 36 시간 동안 수침시킨 후에, 수침시킨 콩을 건져내고, 이를 27 ℃에서 84 시간 동안 발아시켜 발아콩을 제조하였다.After adding 10 times purified water based on the mass of commercially available black soybeans and soaking for 36 hours at 25 ° C., the soaked beans were taken out and germinated at 27 ° C. for 84 hours to prepare germinated beans.

상기 제조된 발아콩에 상기 발아콩 질량의 10배의 1,3-부틸렌글리콜를 첨가하여 상기 발아콩이 모두 잠기게 한 후에, 3일간 15℃ 내지 20℃상온에서 냉침추출법을 수행하여 발아콩 추출물을 제조하였다. 상기 수득한 발아콩 추출물을 필터를 이용하여 여과하고 동결건조하여 발아콩 추출물을 수득하였다.
After adding 10 times 1,3-butylene glycol of the germinated soybeans to all the germinated soybeans so as to submerge all the germinated soybeans, germinated soybean extract was performed by cold extraction at 15 ° C. to 20 ° C. for 3 days. Was prepared. The obtained germinated bean extract was filtered using a filter and lyophilized to obtain a germinated bean extract.

한국생명공학연구원Korea Biotechnology Research Institute KCTC11669KCTC11669 2010040720100407

Claims (5)

발아콩 추출물 및 항여드름균 활성을 나타내는 유산균을 포함하는 항여드름 조성물.
Anti-acne composition comprising a germination bean extract and lactic acid bacteria showing anti-acne bacterium activity.
제1항에 있어서,
상기 추출물은 물, 탄소수 1 내지 5의 알코올, 프로필렌글리콜, 1,3-부틸렌글리콜 또는 이들의 혼합용매를 추출용매로 사용하여 제조한 것인 항여드름 조성물.
The method of claim 1,
The extract is an anti-acne composition prepared by using water, alcohol having 1 to 5 carbon atoms, propylene glycol, 1,3-butylene glycol or a mixed solvent thereof as an extraction solvent.
제1항에 있어서,
상기 항균 조성물은 대장균(E.coli), 살모넬라 티피뮤리움(Salmonella typhimurium), 스타필로 코커스 아우레우스(Staphyllococcus aureus), 칸디다 균(Candida albican), 흙곰팡이(Aspergillus niger) 또는 여드름균(Propionibacterium acnes)으로 이루어진 군에서 선택된 1종 이상에 대해 항균활성을 갖는 것을 특징으로 하는 항여드름 조성물.
The method of claim 1,
The antimicrobial composition is E. coli, Salmonella typhimurium, Staphyllococcus aureus, Candida albican, Aspergillus niger or Propionibacterium acnes Anti-acne composition characterized in that it has an antimicrobial activity against at least one selected from the group consisting of.
제1항에 있어서,
상기 항여드름균 활성을 나타내는 유산균은 비피도박테리움 유산균 SPM0308 (KCTC 11669BP) 인 것을 특징으로 하는 항여드름 조성물.
The method of claim 1,
Lactobacillus showing the anti-acne bacterium activity is anti-acne composition characterized in that the Bifidobacterium lactic acid bacteria SPM0308 (KCTC 11669BP).
제1항 내지 제4항 중 어느 한 항에 따른 조성물을 포함하는 약제, 건강기능식품 또는 화장료조성물.A pharmaceutical, nutraceutical or cosmetic composition comprising the composition according to any one of claims 1 to 4.
KR1020110141285A 2011-12-23 2011-12-23 Antimicrobial composition comprising bifidobaterium having antibacterial activity against propionibacterium acnes, and extract of germinated soybean KR20130074825A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020110141285A KR20130074825A (en) 2011-12-23 2011-12-23 Antimicrobial composition comprising bifidobaterium having antibacterial activity against propionibacterium acnes, and extract of germinated soybean

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020110141285A KR20130074825A (en) 2011-12-23 2011-12-23 Antimicrobial composition comprising bifidobaterium having antibacterial activity against propionibacterium acnes, and extract of germinated soybean

Publications (1)

Publication Number Publication Date
KR20130074825A true KR20130074825A (en) 2013-07-05

Family

ID=48988811

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020110141285A KR20130074825A (en) 2011-12-23 2011-12-23 Antimicrobial composition comprising bifidobaterium having antibacterial activity against propionibacterium acnes, and extract of germinated soybean

Country Status (1)

Country Link
KR (1) KR20130074825A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101999531B1 (en) * 2018-06-20 2019-07-15 재단법인 발효미생물산업진흥원 Lactobacillus perolens SRCM102283 strain having immunity activity, antiviral activity and probiotics properties and uses thereof
KR102001990B1 (en) * 2018-06-20 2019-07-19 재단법인 발효미생물산업진흥원 Pediococcus acidilactici SRCM102615 strain having immunity activity, antiviral activity and probiotics properties and uses thereof
KR102001992B1 (en) * 2018-06-20 2019-07-19 재단법인 발효미생물산업진흥원 Pediococcus acidilactici SRCM102607 strain having immunity activity, antiviral activity and probiotics properties and uses thereof
KR102296290B1 (en) 2020-12-31 2021-09-01 주식회사 바이오뱅크힐링 Bifidobacterium adolescentis strain, and vesicles from thereof and anti-inflammation and anti-bacteria uses of thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101999531B1 (en) * 2018-06-20 2019-07-15 재단법인 발효미생물산업진흥원 Lactobacillus perolens SRCM102283 strain having immunity activity, antiviral activity and probiotics properties and uses thereof
KR102001990B1 (en) * 2018-06-20 2019-07-19 재단법인 발효미생물산업진흥원 Pediococcus acidilactici SRCM102615 strain having immunity activity, antiviral activity and probiotics properties and uses thereof
KR102001992B1 (en) * 2018-06-20 2019-07-19 재단법인 발효미생물산업진흥원 Pediococcus acidilactici SRCM102607 strain having immunity activity, antiviral activity and probiotics properties and uses thereof
KR102296290B1 (en) 2020-12-31 2021-09-01 주식회사 바이오뱅크힐링 Bifidobacterium adolescentis strain, and vesicles from thereof and anti-inflammation and anti-bacteria uses of thereof

Similar Documents

Publication Publication Date Title
KR101968894B1 (en) Composition comprising Streptococcus pneumoniae strain and culture medium thereof
KR101980071B1 (en) Composition comprising Streptococcus thermophilus strain and culture medium thereof
US11857581B2 (en) Antiviral methods and compositions comprising probiotic bacterial molecules
Aarti et al. In vitro investigation on probiotic, anti-Candida, and antibiofilm properties of Lactobacillus pentosus strain LAP1
US9763988B2 (en) Nano-sized kimchi lactic acid bacteria
KR101741165B1 (en) A pharmaceutical or food composition containing the fermentative products of balloon flower converted biologically by Basidiomycota hyphae or lysate of Basidiomycota hyphae with anti-allergenic effect
KR102052056B1 (en) Lactobacillus plantarum having antibacterial activity and uses thereof
CN102071162A (en) Bacillus subtilis LFB112 as well as bacteriocin produced by same and application thereof
CN108697743A (en) For treating the composition for infecting the especially lactic acid bacteria of acne caused by propionibacterium acnes
KR20160097539A (en) Composition comprising Lactobacillus sakei derived from Lonicera japonica Thunb. or cultured products thereof as a active ingredient
KR102052047B1 (en) Pediococcus pentosaceus having antibacterial activity and uses thereof
KR101466317B1 (en) A composition for inhibiting cancer metastasis comprising Hwangryunhaedoktang or its product fermented by lactic acid bacteria
KR20130074825A (en) Antimicrobial composition comprising bifidobaterium having antibacterial activity against propionibacterium acnes, and extract of germinated soybean
Zhang et al. The isolation and identification of Candida glabrata from avian species and a study of the antibacterial activities of Chinese herbal medicine in vitro
KR20220092787A (en) A novel Lactobacillus paracasei strain and uses thereof
KR101911349B1 (en) Novel Actinokineospora sp. R434 having anti-bacterial, anti-oxidant, skin-whitening and anti-wrinkle effect
KR20200084829A (en) Composition for anti-virus Comprising Nano-Sized Lactic Acid Bacteria from Kimchi
KR100526992B1 (en) Fermented extract of a fruit of the trifoliate orange, and a composition for treating the disease caused by infection of helicobacter pylori
KR20110127342A (en) Bifidobaterium spm0308 having antibacterial activity against propionibacterium acnes, and antimicrobial composition for improving acne comprising the same or culture fluid of the same acne as an effective component
KR20180110848A (en) A novel Lactobacillus reuteri BM36301 and a Probiotic Benefits of the same
CN116144521A (en) Lactobacillus sakei AMP5104 strain and application thereof
Ajah In vitro and in vivo studies on the antifungal activity of probiotics and seaweed extract (Ascophyllum nodosum)
KR102598869B1 (en) Selective antimicrobial use of Micrococcus luteus
KR20190129322A (en) Composition for anti-virus Comprising Nano-Sized Lactic Acid Bacteria from Kimchi
US20240050493A1 (en) Strains, compositions and methods of use

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid